Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of March 31, 2011, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital: 5,664,445,657 Ordinary shares of 25p each.
- Treasury Shares: 493,224,284 Ordinary shares.
- Total Voting Rights: 5,171,221,373.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of share counts as of a specific date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Important Facts for Investors to Verify
- Confirm the total number of voting rights (5,171,221,373) to determine notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Verify the number of shares held in Treasury (493,224,284) when calculating outstanding share counts.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.